Sponsor

Otsuka Pharmaceutical Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Otsuka Pharmaceutical Co., Ltd. appears in 83 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials83
Recruiting shown4
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Long-term Administration Trial of SEP-363856 in Patients With SchizophreniaNCT07225712 · lead sponsor · 2025-12-22
RECRUITING
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)NCT06875986 · lead sponsor · 2025-04-17
RECRUITING
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute SchizophreniaNCT05325645 · lead sponsor · 2022-07-21
RECRUITING
Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaNCT06036108 · lead sponsor · 2023-10-03
COMPLETED
Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.NCT05712746 · lead sponsor · 2023-03-03
ACTIVE_NOT_RECRUITING
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])NCT05615363 · lead sponsor · 2023-01-10
COMPLETED
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaNCT05326347 · lead sponsor · 2022-05-31
COMPLETED
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With SchizophreniaNCT05119894 · lead sponsor · 2021-11-22
WITHDRAWN
A Phase 2 Trial of OPC-64005 for Major Depressive DisorderNCT04244253 · lead sponsor · 2020-03-03
COMPLETED
A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral DosesNCT04118127 · lead sponsor · 2019-10-17
COMPLETED
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral IntakeNCT03962101 · lead sponsor · 2019-06-17
COMPLETED
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart FailureNCT03772041 · lead sponsor · 2019-01-16
COMPLETED
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeNCT03724942 · lead sponsor · 2018-11-09
COMPLETED
A Long-Term Study of Brexpiprazole in Patients With Major Depressive DisorderNCT03737474 · lead sponsor · 2018-10-04
COMPLETED
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeNCT03620981 · lead sponsor · 2018-08-20
COMPLETED
A Study of Brexpiprazole in Patients With Major Depressive DisorderNCT03697603 · lead sponsor · 2018-07-30
COMPLETED
Phase I Study of OPC-61815NCT03510663 · lead sponsor · 2018-05-08
COMPLETED
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume OverloadNCT03255226 · lead sponsor · 2018-03-07
COMPLETED
Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart FailureNCT03254108 · lead sponsor · 2017-11-06
COMPLETED
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With SchizophreniaNCT02220712 · lead sponsor · 2014-07-01
COMPLETED
Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeNCT02168920 · lead sponsor · 2014-06-11
TERMINATED
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionNCT02105285 · lead sponsor · 2014-04-01
COMPLETED
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionNCT02105272 · lead sponsor · 2014-04-01
COMPLETED
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult VolunteersNCT02108288 · lead sponsor · 2014-04-01
COMPLETED
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive DisorderNCT02046564 · lead sponsor · 2014-02-01
COMPLETED
A Dose-finding Trial of OPC-34712 in Patients With SchizophreniaNCT01451164 · lead sponsor · 2011-10-01
COMPLETED
A Long-term Trial of OPC-34712 in Patients With SchizophreniaNCT01456897 · lead sponsor · 2011-10-01
COMPLETED
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure PatientsNCT01439009 · lead sponsor · 2011-09-01
COMPLETED
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaNCT01942148 · lead sponsor · 2010-08-01
COMPLETED
A Short Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaNCT01942161 · lead sponsor · 2010-08-01
COMPLETED
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease PatientsNCT01631825 · lead sponsor · 2009-10-01
COMPLETED
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease PatientsNCT01628926 · lead sponsor · 2009-06-01
COMPLETED
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive DisorderNCT00882362 · lead sponsor · 2009-03-01
COMPLETED
To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00917150 · lead sponsor · 2009-03-01
COMPLETED
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive DisorderNCT00876343 · lead sponsor · 2009-03-01
COMPLETED
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)NCT00791999 · lead sponsor · 2008-11-01
COMPLETED
Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)NCT00791921 · lead sponsor · 2008-11-01
COMPLETED
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease PatientsNCT01628965 · lead sponsor · 2008-01-01
COMPLETED
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)NCT00544869 · lead sponsor · 2007-10-01
COMPLETED
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease PatientsNCT00537485 · lead sponsor · 2007-09-01
COMPLETED
A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)NCT00525265 · lead sponsor · 2007-09-01
COMPLETED
A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)NCT00462670 · lead sponsor · 2007-04-01
COMPLETED
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsNCT01631812 · lead sponsor · 2006-12-01
COMPLETED
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-NCT00392197 · lead sponsor · 2006-11-01
COMPLETED
A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease PatientsNCT01628848 · lead sponsor · 2006-08-01
COMPLETED
Exploratory Study for Dry Mouth in Patients With Sjögren's SyndromeNCT00233363 · lead sponsor · 2005-04-15
COMPLETED
A Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsNCT01634243 · lead sponsor · 2005-01-01
COMPLETED
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)NCT00234104 · lead sponsor · 2004-08-01
COMPLETED
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive DisordersNCT05962216 · collaborator · 2023-07-01
RECRUITING
REWIRE: Real-world Engagement With Interventional and Rejoyn EffectivenessNCT07792252 · collaborator · 2026-09-01
NOT_YET_RECRUITING
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use DisorderNCT03526354 · collaborator · 2018-06-19
COMPLETED
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia PatientsNCT03839251 · collaborator · 2018-06-01
COMPLETED
Comparison of the Effectiveness of Brexpiprazole With That of RisperidoneNCT02758067 · collaborator · 2016-06-01
WITHDRAWN
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With ImpulsivityNCT02194933 · collaborator · 2015-02-01
COMPLETED
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and IrritabilityNCT02212613 · collaborator · 2014-09-01
WITHDRAWN
Real Life Assessment of Abilify MaintenaNCT02131415 · collaborator · 2014-05-01
TERMINATED
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase InhibitorNCT02006654 · collaborator · 2014-03-01
COMPLETED
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute SchizophreniaNCT02054702 · collaborator · 2014-02-01
COMPLETED
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With DonepezilNCT02006641 · collaborator · 2014-02-01
COMPLETED
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode SchizophreniaNCT02013622 · collaborator · 2013-11-01
COMPLETED

Drugs studied in this sponsor's trials

14 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Otsuka Pharmaceutical Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo20
brexpiprazole18
tolvaptan4
aripiprazole3
latanoprost Ophthalmic Solution2
rotigotine2
brexpiprazole 1 MG1
brexpiprazole 3 MG1
placebo RxCUI 8375 · Lead sponsor in 12 linked trial(s) · 1 currently recruiting 20 trials brexpiprazole RxCUI 1658314 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 18 trials tolvaptan RxCUI 358257 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 4 trials aripiprazole RxCUI 89013 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials latanoprost Ophthalmic Solution RxCUI 377441 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials rotigotine RxCUI 616739 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials brexpiprazole 1 MG RxCUI 1658330 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial brexpiprazole 3 MG RxCUI 1658338 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial latanoprost RxCUI 43611 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin RxCUI 139462 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial procaterol RxCUI 34530 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial risperidone RxCUI 35636 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ropinirole RxCUI 72302 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial tiotropium RxCUI 69120 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor48
collaborator35
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.